Background: Glomerulonephritis commonly causes kidney failure. Immunosuppres-
Introduction
Glomerulonephritis is associated with end-stage renal disease (ESRD) and significant mortality. 1 Immunosuppressive therapy is often required to reduce inflammation and accrual damage that cause chronic kidney disease (CKD) or ESRD, but immunosuppressants such as glucocorticosteroid and calcineurin inhibitors can be diabetogenic. Current knowledge on diabetes mellitus after immunosuppressant treatment is generally derived from studies on steroid-induced diabetes in non-CKD populations, such as those with rheumatologic disease, 2 but glucose homeostasis may be extremely altered in patients with renal disease. 3 New-onset diabetes after transplant is associated with ESRD and increased mortality, 4 but data extrapolated from the extensive studies in transplant may not apply to patients with glomerulonephritis since immunosuppressive regimens to prevent and treat rejection in kidney transplant are generally more intensive and of longer duration. Knowledge of incidence and outcome of new-onset diabetes in glomerulonephritis treated with usual clinical care, outside of clinical trials, is scant, 5 despite potentially increased risks of ESRD and cardiovascular disease if diabetes occurs in patients with glomerulonephritis and CKD.
Since such information is relevant to both clinicians and patients in weighing immunosuppressant options and planning appropriate monitoring, we aimed to assess the epidemiology, risk factors, and outcomes for new-onset diabetes among patients with glomerular disease (NODAG) treated in real-world clinical practice.
Methods
This was a retrospective cohort study of adults with biopsy-proven glomerulonephritis diagnosed between 1 January 2011 and 31 July 2015 at the Department of Renal Medicine, Singapore General Hospital, a tertiary referral institution. Subjects were identified from the kidney biopsy procedural log, which records all native kidney biopsies performed in our centre. Patients younger than 21 years, those with kidney allograft biopsy, biopsy-proven diabetic nephropathy or pre-existing diabetes mellitus, defined as physician-diagnosed diabetes, fasting glucose ≥7 mmol/L, glycated haemoglobin (HbA1c) ≥6.5% or requiring antidiabetic medications, were excluded. Demographic, comorbidity, laboratory and pharmacotherapy data were retrieved from electronic medical records. Laboratory data collected included peak serum creatinine and the urine proteinto-creatinine ratio (UPCR) within 1 month before kidney biopsy; most recent HbA1c and fasting glucose within 6 months; fasting triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) within 24 months preceding biopsy. Postbiopsy and post-immunosuppressant fasting glucose and peak levels of HbA1c, fasting glucose, TG, LDL-C and HDL-C were recorded for 6 months. All laboratory investigations were conducted at our centre's laboratory, which is accredited by the College of American Pathologists. The estimated glomerular filtration rate (eGFR) was calculated using the CKD EPI estimation equation. 6 Pharmacotherapy data retrieved included the use of renin-angiotensin-aldosterone-system blocker, lipidlowering agents and immunosuppressant prior to and after kidney biopsy, as well as the peak daily dose and the therapy duration of each medication.
Using modified American Diabetes Association (ADA) criteria for type 2 diabetes published in 2010, 7 the primary outcome of NODAG was present if postkidney biopsy fasting venous glucose was ≥7 mmol/L for two or more readings, HbA1c was ≥6.5% or if patient required antidiabetic medications. For patients with NODAG, we also ascertained the type and the therapy duration of antidiabetic medications. Secondary outcomes were ESRD, cardiovascular disease and death. ESRD was defined as eGFR <15 mL/min/1.73 m 2 
Results
Demographic, renal function and metabolic profile of 448 patients with biopsy-proven glomerulonephritis are presented in Table 1 . The study cohort was multiethnic (Chinese 76.8%, Malay 12.3%, Indians 3.8% and other ethnicities 7.1%). A third (39.7%) were the incipient elderly (≥50 years) and 13.6% were elderly (≥65 years). Half the cohort (n = 215, 48.0%) had CKD Stage 3 or worse, defined by eGFR <60 mL/min/1.73 m 2 , and more than half had nephrotic-range proteinuria (UPCR >3 g/g) at biopsy. Baseline fasting glucose and HbA1c were available in 325 and 137 patients respectively; 122 patients (27.2%) had impaired fasting glucose (IFG), defined by ADA in 2010 as fasting glucose between 5.6 and 6.9 mmol/L or HbA1c between 5.7% and 6.4%. 7 Lupus nephritis (n = 110, 24.6%) and minimal change disease or focal segmental glomerulosclerosis (n = 124, 27.7%) were the most common diagnoses, followed by immunoglobulin A nephropathy (n = 97, 21.7%), membranous nephropathy (n = 50, 11.2%) and others (n = 67, 14.9%). The majority received immunosuppressants after diagnosis (n = 323, 72.1%), including prednisolone at peak daily dose of 50 (30, 60) mg per day for 29.4 (12.7, 60.9) months.
NODAG occurred in 48 patients (10.7%); these patients had at least two readings of fasting glucose ≥7 mmol/L (n = 28), HbA1c ≥6.5% (n = 18) and/or antidiabetic medication (n = 22). Figure 1 shows the occurrence of NODAG according to the degree of proteinuria. Time from biopsy to peak fasting hyperglycaemia and HbA1c was 9.1 (0.8, 26.2) and 19.0 (9.4, 28.1) weeks respectively. Antidiabetic medications were started at 6.2 (1.7, 20.0) months from biopsy: all required oral glucose-lowering agents and two patients required insulin. Among those with NODAG after immunosuppressive therapy (n = 47), time from immunosuppressant to antidiabetic medication was 2.8 (0.1, 12.7) months. Among 22 patients treated pharmacologically for NODAG, 1 died and 2 were lost to follow up while 11 and 10 patients still required antidiabetic medications at 12 and 24 months after immunosuppressant initiation respectively. Table 1 compares patients with and without NODAG. Patients with NODAG had significantly greater proteinuria, higher fasting glucose levels and lower fasting HDL-C levels. Both methylprednisolone and Categorical variables are expressed as number (percentage) and compared using the chi-square or Fisher's exact test as appropriate. Continuous variables are expressed as median (IQR) and compared using the Mann-Whitney U test. BP, blood pressure; CKD EPI eGFR, estimated glomerular filtration rate calculated using the chronic kidney disease EPI formula; CVD, cardiovascular disease; ESRD, end-stage renal disease; HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein cholesterol; IFG, impaired fasting glucose; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; MMF, mycophenolate mofetil or sodium; NODAG, new-onset diabetes among patients with glomerular disease; RAAS, renin-angiotensin-aldosterone system; TG, triglyceride; UPCR, urine protein-to-creatinine ratio.
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cyclophosphamide were more commonly used among patients with NODAG (Table 1) . Use, peak daily dose and cumulative duration of prednisolone, cyclosporine, tacrolimus, mycophenolate mofetil or sodium, azathioprine and hydroxychloroquine were not significantly different among patients with NODAG compared to those without. Table 2 shows the univariate and multivariate OR and 95% CI for factors associated with NODAG. Hyperlipidaemia, greater proteinuria, lower HDL-C levels and methylprednisolone use were independently associated with development of NODAG in Model 1. Although HbA1c criteria for diagnosis of diabetes and IFG were recommended by ADA and utilised in this study, interpretation of the A1C assay in renal disease is controversial as red-cell turnover is altered. 8 To explore if the inclusion of HbA1c criteria in IFG definition affected the results, we repeated the multivariate analysis using IFG defined by fasting glucose criteria alone. The associations between the identified risk factors and NODAG remained consistent regardless of HbA1c criteria for IFG. As lower HDL-C levels may contribute to higher TG-to-HDL-C ratios (TG/HDL-C) known to correlate with insulin resistance in diabetic and healthy cohorts, 9-11 TG/HDL-C was substituted for HDL-C in a second multivariate model ( Table 2 ). The association between proteinuria and methylprednisolone with NODAG persisted after adjusting for TG/HDL-C. To examine the consistency of the association between these factors and NODAG, we performed subgroup analysis stratified by age and antilipid medication use after biopsy (Table 3) . Methylprednisolone remained strongly associated with NODAG regardless of age group and in those treated with antilipid medication.
Median follow up was 39.6 (IQR: 26.9, 57.2) months. ESRD occurred in 44 patients (9.8%) at 13.3 (0.7, 34.4) months from diagnosis. There were no differences in ESRD, time to ESRD, cardiovascular disease or death among patients with NODAG compared to those who did not develop NODAG (Table 1) .
Discussion
This study used ADA criteria to define new-onset diabetes and confirmed it occurred in a 10th of patients with glomerular disease, usually after immunosuppressants. We found higher baseline glucose and IFG to be associated with NODAG, consistent with similar findings in solid-organ transplant. [12] [13] [14] Hyperlipidaemia and lower HDL-C were associated with NODAG in our cohort, as well as incident diabetes in individuals with systemic lupus erythematosus and in the general population, likely reflecting the underlying metabolic syndrome. 15, 16 We also found proteinuria to be associated with NODAG (Fig. 1) . Patients with greater proteinuria may be more likely to be treated with prednisolone since those who received prednisolone had greater proteinuria than those who did not receive prednisolone (median UPCR 3.89, (IQR 1.93, 8.49) g/g vs 2.03 (1.12, 4.62) g/g, P < 0.001). Pearson correlation did not find proteinuria to be associated with prednisolone peak daily dose (r = 0.04, P = 0.40) or the cumulative prednisolone duration (r = −0.08, P = 0.13); peak daily prednisolone dose and cumulative duration were also not significantly different .20 on univariate analysis were chosen for stepwise binary logistic regression: age, systolic BP, hyperlipidaemia, eGFR, UPCR, IFG, HDL-C, TG/HDL-C, prednisolone, methylprednisolone, cyclosporine and cyclophosphamide. OR of variables removed during stepwise regression are not included. §Postbiopsy immunosuppressants. BP, blood pressure; CI, confidence interval; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; IFG, impaired fasting glucose; NODAG, new-onset diabetes mellitus among patients with glomerular disease; OR, odds ratio; TG, triglyceride; UPCR, urine protein-to-creatinine ratio.
among those with incident diabetes compared with those without. However, the association between proteinuria and incident diabetes persisted after taking into account renal function and prednisolone use ( Table 2) . Although none of the few studies of incident diabetes in glomerular or renal disease assessed proteinuria, 5, 17, 18 our finding is consistent with data in the transplant and general populations. 16, 19, 20 Among nondiabetic renal transplant patients, albuminuria correlated with homeostasis model assessment for insulin resistance, 21 but in healthy individuals, albuminuria was not associated with hyperinsulinaemia and predicted diabetes development independent of the metabolic syndrome.
16,22-24 Roland et al. postulated that proteinuria is a marker for systemic vascular endothelial dysfunction, which may also involve the pancreas, leading to impaired islet cell function and reduced insulin secretion. 19 The role of renal dysfunction in diabetes is again controversial: while insulin resistance is common in CKD and thus predisposes individuals with CKD to hyperglycaemia, reduced glucose reabsorption and gluconeogenesis by kidney tubular cells in renal dysfunction lower the serum glucose concentration. 3 We noted poorer renal function in patients who had incident diabetes, although the difference was not statistically significant. Similarly, two small cohort studies involving patients with renal disease found that eGFR values in patients who developed diabetes were lower than those who did not. 5, 18 Incidence of diabetes in this cohort treated with usual clinical care, which included all immunosuppressants and non-immunosuppressant therapy commonly used in treating glomerulonephritis, was lower compared with cohorts treated solely with high-dose steroid monotherapy. Steroid-induced diabetes occurred in 40% of a small cohort of 42 patients with nondiabetic primary renal diseases. 17 Another retrospective cohort study of 95 hospitalised IgA nephropathy patients diagnosed incident diabetes in 20% after treatment with tonsillectomy and pulse methylprednisolone. 5 We evaluated all immunosuppressants commonly used in the routine treatment of glomerulonephritis and found methylprednisolone to be strongly associated with NODAG, consistent with known hyperglycaemic effects of glucocorticosteroids under various conditions, including haematologic malignancies and inflammatory rheumatic, respiratory and neurologic diseases. 2 Calcineurin inhibitors are known to be associated with post-transplant diabetes; 4,25 the diabetogenic effect of tacrolimus is mediated through reduced insulin secretion by pancreatic β-islet cells and is dose-dependent. 26 We postulate that tacrolimus was not associated with incident diabetes in this study possibly because tacrolimus was infrequently used in our cohort and doses are generally lower in glomerulonephritis treatment compared to high-dose antirejection therapy in the early post-transplant period when post-transplant .20 on univariate analysis were chosen for stepwise binary logistic regression: age, systolic blood pressure, hyperlipidaemia, eGFR, UPCR, impaired fasting glycaemia, TG/HDL-C ratio, prednisolone, methylprednisolone, cyclosporine and cyclophosphamide use after kidney biopsy. OR of variables removed during stepwise regression are not included. CI, confidence interval; IFG, impaired fasting glucose; NODAG, new-onset diabetes mellitus among patients with glomerular disease; OR, odds ratio; UPCR, urine protein-to-creatinine ratio. Figure 1 New-onset diabetes mellitus among patients with glomerular disease (NODAG) according to severity of proteinuria measured by the urine protein-to-creatinine ratio (UPCR).
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Internal Medicine Journal 49 (2019) 101-108diabetes incidence is highest. 26 Cyclophosphamide is known to accelerate autoimmune diabetes in mice, 27, 28 and contributed to diabetes onset in a single case report. 29 While it was associated with metabolic syndrome among lupus patients, the association was diminished after adjusting for age, body mass index (BMI) and proteinuria. 30 Other immunosuppressants, such as mycophenolate mofetil and hydroxychloroquine, have been reported to affect diabetes risks in a few rheumatologic cohorts. 15, 31, 32 Concurrent mycophenolate use with high-dose glucocorticosteroids predisposed Koreans with systemic lupus erythematosus to diabetes, 31 while hydroxychloroquine reduced diabetes risk in Taiwanese and Malaysians with lupus. 15, 32 More recently, meta-analyses of trials and observational studies found that statin increased diabetes risk. 33, 34 We found that use of antilipid medication modified associations between the identified factors and NODAG (Table 3) . A postulated mechanism is through increased synthesis of proprotein convertase subtilisin/ kexin type 9 (PCSK9), an enzyme regulating circulating LDL-C levels recently found to be independently associated with post-transplant diabetes. 35 Although LDL-C levels and antilipid medications were not associated with incident diabetes in this study, the role of PCSK9 in diabetes should be explored further. Another potentially modifiable risk factor for diabetes is hepatitis C virus (HCV) infection. 36 We were unable to assess its role in our study since only two patients had HCV.
Limitations of this study include the retrospective nature with limited data on other markers of insulin resistance, such as BMI, waist-to-hip ratio and fasting insulin levels. Instead, we adjusted for TG/HDL-C as a surrogate for insulin resistance. [9] [10] [11] Although our department Glomerulonephritis Disease Management Clinic recommends monitoring fasting glucose 2 months after immunosuppressant initiation, there is no routine monitoring for metabolic changes in patients not treated with immunosuppressants. Thus, the incidence of diabetes may be underestimated among these patients. Causality cannot be conclusively established in this observational study. Prospective randomised studies to evaluate costeffectiveness of assessing the metabolic complications among individuals with glomerulonephritis will be required to inform best clinical practice. Currently, there are no guidelines for monitoring incident diabetes among individuals with glomerulonephritis, 37, 38 although consensus guidelines suggest that kidney transplant patients should be monitored with fasting glucose at least weekly for 4 weeks then every 3 months for 1 year. 39 Since we found that half the patients with incident diabetes after immunosuppressive therapy required antidiabetic medication within 3 months of initiating immunosuppressants, the authors propose that individuals with risk factors for diabetes be screened monthly for osmotic symptoms of hyperglycaemia and fasting or postprandial glucose for the first 3 months of immunosuppressive therapy. Although ADA endorsed the use of HbA1c for diagnosis of diabetes, 7 its use in screening for NODAG may be limited since the onset of diabetes after immunosuppressant or steroid therapy is rapid. The HbA1c assay may also be inaccurate in patients with glomerulonephritis who often have altered red-cell turnover due to chronic disease or immunosuppression. 8 
Conclusion
Greater proteinuria and methylprednisolone were independently associated with incident diabetes among individuals with glomerular disease, hence the authors suggest that at-risk patients should be appropriately counselled and monitored for hyperglycaemia.
